Trial reportDigestive diseases and sciences2006
Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial.
Trial report in Digestive diseases and sciences, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- L-Carnitine in the Treatment of Psychiatric and Neurological Manifestations: A Systematic Review.Nutrients · 2024Pooled it
- Acetyl-L-carnitine for patients with hepatic encephalopathy.The Cochrane database of systematic reviews · 2019Pooled it
- Is oral L-acyl-carnitine an effective therapy for hepatic encephalopathy? Review of the literature.Digestive diseases and sciences · 2008Pooled it
- Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.The Korean journal of internal medicine · 2022Trial
- Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.Metabolic brain disease · 2011Trial
- Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.Digestive diseases and sciences · 2008Trial
- The role of genetic defects in carnitine-associated hepatic encephalopathy: a review of literature.Gastroenterology and hepatology from bed to bench · 2024Review
- Novel Agents in the Management of Hepatic Encephalopathy: A Review.Journal of clinical and translational hepatology · 2021Review
- Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update.Frontiers in medicine · 2021Review
- Effect of L-carnitine on health-related quality of life in patients with liver cirrhosis.Biomedical reports · 2020Article
- Review
- Review
- Endozepine-4 levels are increased in hepatic coma.World journal of gastroenterology · 2015Article
- A review on the role of L-carnitine in the management of tamoxifen side effects in treated women with breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Acetyl-L-carnitine in hepatic encephalopathy.Metabolic brain disease · 2013Review
- Serum carnitine levels and levocarnitine supplementation in institutionalized Huntington's disease patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Acetyl-L-carnitine prevents carbon tetrachloride-induced oxidative stress in various tissues of Wistar rats.Journal of physiology and biochemistry · 2011Article
- Current concepts in the pathophysiology and management of hepatic encephalopathy.Gastroenterology & hepatology · 2011Article
- Role of carnitine in disease.Nutrition & metabolism · 2010Article
- Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple therapeutic modalities have been used to treat hepatic encephalopathy. L: -Acetylcarnitine (LAC) is a physiologically active substance that improves both the energetic and the neurotransmission profiles. LAC is able to cross the hematoencephalic barrier and reach the cerebral regions, where the acetylic group may be utilized. The aim of this work was to evaluate the efficacy of LAC in the treatment of hepatic coma in cirrhotic patients. Twenty-four suitably selected patients were enrolled in the study and, following randomization, received either LAC (n=13) or placebo (n=11). Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment. In the placebo group we observed two cases of improved neurological findings as well as one case of improved EEG grading. In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively. Noteworthily, seven (54%) patients went from grade 4 down to grade 3, and one from grade 4 down to grade 1. The improvement in the neurological picture was evident at between 1 and 4 hr after the end of treatment, remaining until 24 hr after. No side effects were observed in our study series. Our study demonstrates that LAC administration improved neurological and biohumoral symptoms in selective cirrhotic patients with hepatic coma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.